Supplementary Figure S5 from The Oncogenic <i>EGFR–SHC1</i> Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer

<jats:p>&lt;p&gt;Supplementary Figure S5 shows that dual inhibition of afatinib plus SRC-TKIs represents a potential treatment strategy for EGFR-SHC1-driven tumors, including immunoblotting analyses of downstream signaling following combination treatment with afatinib and tirbanibulin, dose-response curves for the combination in Ba/F3-EGFR-SHC1 cells, and validation experiments using SRC knockdown or SHC1-inactivated mutants to confirm that the synergistic effects of dasatinib and afatinib are mediated through SRC-dependent SHC1 signaling.&lt;/p&gt;</jats:p>